Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q15043

UPID:
S39AE_HUMAN

ALTERNATIVE NAMES:
LIV-1 subfamily of ZIP zinc transporter 4; Solute carrier family 39 member 14; Zrt- and Irt-like protein 14

ALTERNATIVE UPACC:
Q15043; A6NH98; B4DIW3; B6EU88; D3DSR4; Q6ZME8; Q96BB3

BACKGROUND:
ZIP14, a key player in metal ion homeostasis, mediates the uptake of essential metals like zinc, manganese, and iron, crucial for various biological processes including development, immunity, and metabolism. By transporting these metals in an electroneutral complex with bicarbonate ions, ZIP14 ensures their proper cellular distribution. Its role extends to the regulation of gluconeogenesis, chondrocyte differentiation, and cellular response to endoplasmic reticulum stress, underlining its multifaceted biological significance.

THERAPEUTIC SIGNIFICANCE:
Given ZIP14's critical function in managing cellular metal ion levels and its association with specific metabolic disorders, it represents a promising target for drug discovery. The protein's link to Hypermanganesemia with dystonia 2 and Hyperostosis cranialis interna underscores the therapeutic potential in modulating ZIP14 activity for disease intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.